Trading over 12 years, with an emphasis in small cap biotech. Passionate about science and cooking.
"Win or lose, everybody gets what they want out of the market. Some people seem to like to lose, so they win by losing money."
Dr. Schwartz is a 30-year veteran of the Pharmaceutical Industry most recently in the role of Executive Director, Strategic Transactions for Bristol-Myers Squibb Company where he has more than a dozen completed transactions to his credit. He speaks frequently on the Biotech-Big Pharma dynamics and evolving research and treatment paradigms in oncology and is perhaps best known for predicting FDA’s rejection of Dendreon’s Provenge vaccine in 2007 (San Francisco Chronicle, March 30, 2007). Provenge ultimately won FDA approval in April, 2010.
Dr. Schwartz founded RHS Advisors, LLC, a life-sciences consulting firm, in July 2010.
Larry White is a featured analyst at ElliottWaveTrader focusing on mining stocks. Larry joined as a member of EWT in October 2012 and quickly shifted his focus to mining stocks as well as the GDX and GDXJ mining ETFs. Prior to trading, held management and executive roles for organizations such as Toshiba, ISOETEC, and Panasonic.